|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
1997-11-21
|
|
pubmed:abstractText |
Neutralizing polyclonal antibody to respiratory syncytial virus (RSV) has been shown to be an effective prophylactic agent when administered intravenously in high-risk infants. This study describes the generation of a humanized monoclonal antibody, MEDI-493, that recognizes a conserved neutralizing epitope on the F glycoprotein of RSV. The affinity of MEDI-493 was found to be equal to or slightly better than an isotype-matched chimeric derivative of the parent antibody. In plaque reduction, microneutralization, and fusion-inhibition assays, MEDI-493 was significantly more potent than the polyclonal preparation. Broad neutralization of a panel of 57 clinical isolates of the RSV A and B subtypes was demonstrated. Pretreatment of cotton rats with MEDI-493 resulted in 99% reduction of lung RSV titers at a dose of 2.5 mg/kg, corresponding to a serum concentration of 25-30 microg/mL. Further, MEDI-493 did not induce increased RSV infection or pathology in either a primary or a secondary challenge.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0022-1899
|
|
pubmed:author |
pubmed-author:BansalGG,
pubmed-author:CouchenourDD,
pubmed-author:DormitzerMM,
pubmed-author:HallW CWC,
pubmed-author:HemmingV GVG,
pubmed-author:JohnsonSS,
pubmed-author:KoenigSS,
pubmed-author:O'GradyJJ,
pubmed-author:OliverCC,
pubmed-author:PfarrD SDS,
pubmed-author:PrinceG AGA,
pubmed-author:TamuraJ KJK,
pubmed-author:TsaoEE,
pubmed-author:WangS CSC,
pubmed-author:WoodsRR,
pubmed-author:YoungJ FJF
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
176
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1215-24
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:9359721-Amino Acid Sequence,
pubmed-meshheading:9359721-Animals,
pubmed-meshheading:9359721-Antibodies, Monoclonal,
pubmed-meshheading:9359721-Antibodies, Viral,
pubmed-meshheading:9359721-HN Protein,
pubmed-meshheading:9359721-Humans,
pubmed-meshheading:9359721-Molecular Sequence Data,
pubmed-meshheading:9359721-Respiratory Syncytial Virus, Human,
pubmed-meshheading:9359721-Respiratory Syncytial Virus Infections,
pubmed-meshheading:9359721-Sigmodontinae,
pubmed-meshheading:9359721-Viral Envelope Proteins,
pubmed-meshheading:9359721-Viral Proteins
|
|
pubmed:year |
1997
|
|
pubmed:articleTitle |
Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus.
|
|
pubmed:affiliation |
MedImmune Inc., Gaithersburg, Maryland 20878, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.
|
